"Receptors, Thrombin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of proteinase-activated receptors that are specific for THROMBIN. They are found primarily on PLATELETS and on ENDOTHELIAL CELLS. Activation of thrombin receptors occurs through the proteolytic action of THROMBIN, which cleaves the N-terminal peptide from the receptor to reveal a new N-terminal peptide that is a cryptic ligand for the receptor. The receptors signal through HETEROTRIMERIC GTP-BINDING PROTEINS. Small synthetic peptides that contain the unmasked N-terminal peptide sequence can also activate the receptor in the absence of proteolytic activity.
Descriptor ID |
D018179
|
MeSH Number(s) |
D12.776.395.550.625.800 D12.776.543.550.625.800 D12.776.543.750.695.875 D12.776.543.750.705.675.892 D12.776.543.750.750.850 D12.776.543.750.792.500
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Thrombin".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Glycoproteins [D12.776.395]
- Membrane Glycoproteins [D12.776.395.550]
- Platelet Membrane Glycoproteins [D12.776.395.550.625]
- Receptors, Thrombin [D12.776.395.550.625.800]
- Membrane Proteins [D12.776.543]
- Membrane Glycoproteins [D12.776.543.550]
- Platelet Membrane Glycoproteins [D12.776.543.550.625]
- Receptors, Thrombin [D12.776.543.550.625.800]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, G-Protein-Coupled [D12.776.543.750.695]
- Receptors, Thrombin [D12.776.543.750.695.875]
- Receptors, Immunologic [D12.776.543.750.705]
- Platelet Membrane Glycoproteins [D12.776.543.750.705.675]
- Receptors, Thrombin [D12.776.543.750.705.675.892]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Thrombin [D12.776.543.750.750.850]
- Receptors, Proteinase-Activated [D12.776.543.750.792]
- Receptors, Thrombin [D12.776.543.750.792.500]
Below are MeSH descriptors whose meaning is more specific than "Receptors, Thrombin".
This graph shows the total number of publications written about "Receptors, Thrombin" by people in this website by year, and whether "Receptors, Thrombin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1997 | 0 | 1 | 1 |
2000 | 0 | 1 | 1 |
2009 | 1 | 1 | 2 |
2010 | 0 | 1 | 1 |
2013 | 0 | 2 | 2 |
2014 | 0 | 2 | 2 |
2015 | 1 | 0 | 1 |
2017 | 1 | 1 | 2 |
2018 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Thrombin" by people in Profiles.
-
Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial. Blood Cells Mol Dis. 2018 09; 72:37-43.
-
Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. Am Heart J. 2018 02; 196:28-35.
-
Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. Eur Heart J. 2017 Mar 14; 38(11):804-810.
-
Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial). Am J Cardiol. 2015 May 15; 115(10):1325-32.
-
Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). Am Heart J. 2014 Oct; 168(4):588-96.
-
Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial). Am J Cardiol. 2014 Sep 01; 114(5):665-73.
-
Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial). Am J Cardiol. 2014 Mar 15; 113(6):936-44.
-
Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). J Am Coll Cardiol. 2014 Mar 25; 63(11):1048-57.
-
Plasma kallikrein promotes epidermal growth factor receptor transactivation and signaling in vascular smooth muscle through direct activation of protease-activated receptors. J Biol Chem. 2010 Nov 05; 285(45):35206-15.
-
A new generation of antiplatelet agents. Curr Opin Cardiol. 2009 Jul; 24(4):307-12.